X4 Pharmaceuticals - XFOR Stock Forecast, Price & News

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on XFOR. B. Riley reduced their price objective on X4 Pharmaceuticals from $10.00 to $7.00 and set a "buy" rating for the company in a research report on Thursday, May 19th. HC Wainwright reduced their price objective on X4 Pharmaceuticals from $8.50 to $3.50 in a research report on Friday.

X4 Pharmaceuticals Stock Performance

Shares of NASDAQ:XFOR traded down $0.01 on Tuesday, reaching $1.17. The company had a trading volume of 3,401 shares, compared to its average volume of 221,188. X4 Pharmaceuticals has a twelve month low of $0.86 and a twelve month high of $6.21. The stock has a 50-day moving average price of $1.14 and a 200 day moving average price of $1.45. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.73 and a quick ratio of 4.73.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Rating) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.10). During the same period in the prior year, the business earned ($1.30) earnings per share. On average, equities research analysts predict that X4 Pharmaceuticals will post -1.91 EPS for the current fiscal year.